NBRLBoston has developed the gene and intrabody combo with T and NK cell candidates in R&D for anti-solid tumor and virus (COVID19) infection diseases treatment.
We are looking for the new funds and/or cooperation to move the gene and intrabody combo with T and NK cell therapy candidates forwards
I). Prepare and finish anti- solid tumor leads genes drug candidates, CMC, GMP, and
IND filing
II). Prepare anti-tumor immune gene therapy for clinical study (Phase 0 trial) on
advanced patients with anti-solid tumors (melanoma, liver cancer, lung cancer, breast cancer,
gastric cancer, pancreatic cancer etc.
III). Evaluate the selected new leads therapeutic intrabody candidates in vitro and in vivo
and pre-clinical develop
NBRLBoston and BWH Harvard University have developed novel anti Aβ monoclonal antibody and anti tau and α-Syn bispecific and multi- therapeutic , and antibody and Fc fusion proteins candidates
Next Step R&D
1. Further optimization of generated leads
2. Multiple cell based in vitro function evaluation of the optimized leads
3. Ex-vivo evaluation of the selected leads by using Alzheimer patient’s brain tissue and CSF
4. In vivo animal study by using the different AD model mice and different age with a more stable oAβ AD mice model
5. MOA study to address the key question whether the plaque loads of these mice brains and if clearance of oAβ will lead to plaque removal, which can demonstrate that our leads therapeutics have unique function and better anti-AD efficacy compared with current market and all other R&D biological therapeutics
6. Final selection of lead therapeutics for PK/PD, toxicity study and developability evaluation
